J&J spotlights infectious diseases as pipeline priority

Johnson & Johnson is putting infectious diseases in the spotlight as it outlines ambitious plans to advance new therapies for the flu, HIV and hepatitis C. During its third-quarter review of the numbers for analysts, top execs at J&J left little doubt that recent moves on the contagious disease front will be followed up with plenty of new deals.

To make its case, J&J pointed to the recent buyout pact for Crucell, the maker of vaccines and a one-time partner in a program to develop a new universal flu jab. "We want to make Crucell the center for vaccines in our pharmaceuticals business," Chief Financial Officer Dominic Caruso told analysts yesterday. J&J already sells HIV therapies, and its licensing pact with Vertex on telaprevir gives the pharma company dibs on one of the hottest hepatitis C drugs in late-stage development.

J&J told analysts that the company has 13 drugs either up for an approval or getting close to a regulatory filing. Three of those drugs are up for an approval, two more should be filed in a matter of weeks and there are eight that are expected to land at regulatory agencies between 2011 and 2013. In addition to infectious diseases, J&J has been focused on cancer, neurological disorders and immunological conditions like rheumatoid arthritis.

- here's the story from the Wall Street Journal
- get the report from the Star-Telegram

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.